Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Diarrhea 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 7Nivolumab 4Carboplatin 4Taxes 3Paclitaxel 3Gene Expression Profiling 3rucaparib 2aflibercept 2Radiotherapy 2Polymerase Chain Reaction 2Leucovorin 2Irinotecan 2Interleukin-12 Subunit p35 2Fluorouracil 2Drug Therapy 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2veliparib 1trastuzumab deruxtecan 1tocilizumab 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1cc-486 1cabozantinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Octreotide × Genitourinary × Clear all
NCT00033605 2016-07-13

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Alliance for Clinical Trials in Oncology

Phase 3 Completed
130 enrolled
GastrointestinalGenitourinaryGynecologicSarcoma

Uterine Cervical Neoplasms, Diarrhea, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡